WIZARD and the design of trials for secondary prevention of atherosclerosis with antibiotics

American Heart Journal

Volumn 138, Issue 5 II, 1999, Pages

  Dunne, M ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; PLACEBO;

ANTIBIOTIC THERAPY; ATHEROGENESIS; ATHEROSCLEROSIS; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CONFERENCE PAPER; DISEASE ASSOCIATION; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SECONDARY PREVENTION;

EID: 0032716119     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-8703(99)70297-8     Document Type: Conference Paper

References (5)

1. Pedersen TR, Kjekshus J, Berg K, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Circulation 1994;344:1383-9.
2. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
3. Sacks FM, Pfeffer MA, Moye LA, et al. Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol And Recurrent Events trial (CARE). Am J Cardiol 1991;68:1436-46.
4. Verkooyen RP, Willemse D, Hiep-van Casteren SC, et al. Evaluation of PCR, culture, and serology for diagnosis of Chlamydia pneumoniae respiratory infections. J Clin Microbiol 1998;36:2301-7.
5. Engel JN. Azithromycin-induced block of elementary body formation in Chlamydia trachomatis. Antimicrob Agents Chemother 1992;36:2304-9.